Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Stock Up 2.1 %

AXSM opened at $46.27 on Monday. The company has a current ratio of 2.44, a quick ratio of 2.20 and a debt-to-equity ratio of 6.15. Axsome Therapeutics has a 52-week low of $19.38 and a 52-week high of $48.82. The company has a 50 day moving average of $36.27 and a two-hundred day moving average of $33.75.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.13. During the same quarter in the previous year, the company earned ($0.86) EPS. On average, sell-side analysts predict that Axsome Therapeutics will post -4.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AXSM. Mizuho cut their price objective on shares of Axsome Therapeutics from $51.00 to $49.00 in a research report on Tuesday, May 3rd. Morgan Stanley boosted their price objective on shares of Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 10th. Cowen boosted their price objective on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a research report on Wednesday, June 29th. Cantor Fitzgerald cut their price objective on shares of Axsome Therapeutics from $64.00 to $54.00 in a research report on Wednesday, August 10th. Finally, Cowen boosted their price objective on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a research report on Wednesday, June 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.63.